Skip to main content

Table 2 Unadjusted and adjusted zero-inflated negative binomial models to evaluate the association of anti-PAD4 or anti-PAD4/PAD3 positivity with total radiographic scores for CLEAR I and CLEAR II patients at baseline (cross-sectional analysis) (N = 192)

From: Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans

Predictor/variable Each variable combined with disease duration (BL)
(IRR; 95 % CI)
Multivariablea (BL)
(IRR; 95 % CI)
P value
(multivariable model)
Anti-CCP model
 Anti-CCP 3.87 (1.90, 7.89) 4.48 (2.15, 9.36) <0.001
 RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.06 (1.04, 1.08) <0.001
 Smoking (reference to never smoker)
  Current 1.36 (0.73, 2.50) 1.22 (0.67, 2.25) 0.517
  Former 0.75 (0.39, 1.44) 0.57 (0.29, 1.20) 0.093
Anti-PAD4 model
 Anti-PAD4 1.25 (0.71, 2.22) 1.76 (0.89, 3.46) 0.102
 RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.05 (1.03, 1.07) <0.001
 Smoking (reference to never smoker)
  Current 1.36 (0.73, 2.50) 1.40 (0.76, 2.58) 0.284
  Former 0.75 (0.39, 1.44) 0.54 (0.25, 1.15) 0.110
Anti-PAD4/PAD3 model
 Anti-PAD4/PAD3 cross-reactivity 1.88 (0.88, 4.03) 2.63 (1.16, 5.95) 0.020
 RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.06 (1.04, 1.08) <0.001
 Smoking (reference to never smoker)
  Current 1.36 (0.73, 2.50) 1.30 (0.71, 2.38) 0.403
  Former 0.75 (0.39, 1.44) 0.50 (0.25, 1.00) 0.049
  1. RA medication and age were not significantly associated with the outcome in the bivariable model and therefore were not included in the multivariable model
  2. aMultivariable model adjusted for all the variables included in the table
  3. PAD peptidyl arginine deiminase enzyme, CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, BL baseline data, IRR incidence rate ratio, CI confidence interval, RA rheumatoid arthritis
  4. P values less than 0.05 are shown in bold